A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation

Drug Development and Industrial Pharmacy

Volumn 39, Issue 7, 2013, Pages 996-1004

  Shi, Yijie ^a   Zou, Meijuan ^a   An, Yue ^a   Ji, Zhaoshuai ^a   Gao, Ping ^a   Cheng, Gang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Acid base precipitation; Bioavailability; Gastrointestinal distribution; Microfluidization; Nanosuspensions; Rebamipide

Indexed keywords

POLOXAMER; POVIDONE; REBAMIPIDE;

AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; RAT; STOMACH MUCOSA; SUSPENSION; TABLET; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

ALANINE; ANIMALS; ANTI-ULCER AGENTS; GASTROINTESTINAL TRACT; MALE; MICE; MICROFLUIDIC ANALYTICAL TECHNIQUES; NANOPARTICLES; PARTICLE SIZE; QUINOLONES; RATS; RATS, WISTAR; SOLUBILITY; SUSPENSIONS; X-RAY DIFFRACTION;

EID: 84878821710     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.689765     Document Type: Article

References (36)

1. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644.
2. Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. (2010). Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm, 402:213-220.
3. Singh SK, Srinivasan KK, Gowthamarajan K, Singare DS, Prakash D, Gaikwad NB. (2011). Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm, 78:441-446.
4. Sun W, Mao S, Shi Y, Li LC, Fang L. (2011). Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci, 100:3365-3373.
5. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y et al. (2010). Preparation of stable nitrendipine nanosuspensions using the precipitationultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci, 40:325-334.
6. Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol, 56:827-840.
7. Bosselmann S, Williams RO. (2012). Has nanotechnology led to improved therapeutic outcomes? Drug Dev Ind Pharm, 38:158-170.
8. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796.
9. CDER/FDA. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical classification system. Center for Drug Evaluation and Research 2000.
10. Huang BB, Li GF, Luo JH, Duan L, Nobuaki K, Akira Y. (2008). Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. World J Gastroenterol, 14:4928-4937.
11. Li GF, Wang CX, Yan Y, Kishimoto N, Yamamoto A. (2008). [Permeabilities of rebamipide via different intestinal mucosa in the diffusion chamber in vitro]. Yao Xue Xue Bao, 43: 314-317.
12. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res, 19:921-925.
13. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E et al. (2005). 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci, 50 Suppl 1:S3-S11.
14. Akamatsu T, Nakamura N, Furuya N, Shimizu T, Gotou A, Kiyosawa K et al. (2002). Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig Dis Sci, 47:1399-1404.
15. Shioya Y, Kashiyama E, Okada K, Kusumoto N, Abe Y, Uchida M et al. (1989). Metabolic fate of the anti-ulcer agent, (±)-2-(4- Chlorobenzoylamino)-3-[2(1H)-quinolinon-4 -yl] propionic acid (OPC-12759): absorption, distribution, and excretion in rats and dogs. Iyakuhin Kenkyu, 20:522-533.
16. Kishi H, Ogawa N. (1989). Phase I trial of anti-ulcer drug, Proamipide (OPC-12759). Jpn J Clin Pharmacol Ther, 3: 355-363.
17. Ruell JA, Tsinman O, Avdeef A. (2004). Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules. Chem Pharm Bull, 52:561-565.
18. Chen H, Wan J, Wang Y, Mou D, Liu H, Xu H et al. (2008). A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology, 19:375104.
19. Hou CD, Wang JX, Le Y, Zou HK, Zhao H. (2011). Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Dev Ind Pharm [Online] 1-7. Available at: http:// informahealthcare.com/doi/abs/10.3109/ 03639045.2011.630394. Accessed on 12 April 2012.
20. Gao L, Zhang DR, Chen MH. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 2008;10: 845-862.
21. Avdeef A. (2007). Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev, 59:568-590.
22. Chan HK, Kwok PC. (2011). Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev, 63:406-416.
23. Maa YF, Hsu CC. (1999). Performance of sonication and microfluidization for liquid-liquid emulsification. Pharm Dev Technol, 4:233-240.
24. Mou D, Chen H, Wan J, Xu H, Yang X. (2011). Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm, 413:237-244.
25. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ et al. (2006). Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm, 323:153-160.
26. Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3-16.
27. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19.
28. Aboofazeli R, Barlow DJ, Lawrence MJ. (2000). Particle size analysis of concentrated phospholipid microemulsions I. Total intensity light scattering. AAPS PharmSci, 2:E13.
29. Aboofazeli R, Barlow D, Lawrence MJ. (2000). Particle size analysis of concentrated phospholipid microemulsions II. Photon correlation spectroscopy. AAPS PharmSci, 2:E19.
30. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. (2008). Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci, 35:127-135.
31. Wu W, Nancollas GH. (1998). A new understanding of the relationship between solubility and particle size. J Solution Chem, 27:521-531.
32. Shin BS, Kim CH, Jun YS, Yoon CH, Rho JI, Lee KC et al. (2004). Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. Drug Dev Ind Pharm, 30: 869-876.
33. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989;51:9-17.
34. Jia L, Wong H, Cerna C, Weitman SD. (2002). Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091-1096.
35. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchene D. (1997) Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm, 44: 25-31.
36. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res, 13:1838-1845.